Indole-3-PROpionic Acid Clinical Trials - a Pilot Study

NACompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2025

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Indole-3-propionic acid

A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.

DIETARY_SUPPLEMENT

Placebo

Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.

Trial Locations (1)

2600

Optic Neuritis Clinic, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup, Glostrup Municipality

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

University of Southampton

OTHER

lead

Glostrup University Hospital, Copenhagen

OTHER

NCT06674018 - Indole-3-PROpionic Acid Clinical Trials - a Pilot Study | Biotech Hunter | Biotech Hunter